AstraZeneca CEO Pascal Soriot talked to analysts and reporters for hours Thursday, touting his company's unexpectedly strong second-quarter results. And they were worth touting. But make no mistake: Soriot's remarks were meant for a different audience.
AstraZeneca's internal forecast for a bright future is heavily dependent on a cache of new cancer immunotherapies, and the U.K. drugmaker is planning to test its lead oncology treatment in more and more tumor types with hopes of delivering on a $6.5 billion peak sales estimate.
AstraZeneca has agreed to pay $875 million up front--and up to $2.2 billion total, with milestones--for Almirall's respiratory portfolio. The deal brings a couple of marketed drugs, and a list of pipeline meds that includes a combo drug Almirall is developing with U.S.-based Forest Laboratories.
No news isn't good or bad for Pfizer deal-watchers. It's just no news. Anyone hoping for a halfway-clear idea of CEO Ian Read's next buyout move was disappointed after Tuesday's second-quarter earnings call with analysts.
Demonstrating yet again that AstraZeneca sees a big future for itself in the hot immuno-oncology field, the pharma giant today unveiled another collaboration on a combo for MEDI-4736, its anti-PD-L1 therapy looking to suit up for some blockbuster competition in treating cancer. Japan's Kyowa Hakko Kirin is matching its anti-CCR4 antibody, mogamulizumab, with AstraZeneca's MEDI-4736 to gauge its efficacy and safety in an exploratory Phase I/Ib study. And AstraZeneca will also match its anti-CTLA-4 antibody tremelimumab with Kyowa's drug in a separate combination.
AstraZeneca has signed an agreement to pick up Almirall's respiratory business for up to $2.1 billion, hoping to shoulder its way to the front of a blockbuster market for COPD treatments.
Drugmakers cheer when influential doctors' groups revise treatment guidelines to include new drugs. But as AstraZeneca's MedImmune unit knows, those groups can backpedal.
Drugmakers cheer when doctors' groups revise treatment guidelines to include new drugs. What happens when these powerful professional associations change those recommendations unfavorably? If you're AstraZeneca's MedImmune business, you fight back with sensational newspaper advertising.
AstraZeneca has high hopes for the in-development AZD9291, a treatment for lung cancer expected to bring in $3 billion a year at its peak, and the drugmaker is working with rival Roche to craft a blood test that can spot ideal patients for the therapy.
AstraZeneca's MedImmune has joined up with immunotherapy maker Advaxis to evaluate the Big Pharma's antibody MEDI4736 in conjunction with the Princeton, NJ-based biotech's lead cancer vaccine in patients with HPV-related cancers.